Atea Pharmaceuticals Earnings Estimate

AVIR -  USA Stock  

USD 24.74  0.37  1.47%

Many public companies, such as Atea Pharmaceuticals, manage the perception of their earnings on regular basis to make sure that analyst estimates are accurate. Future earnings calculations are essential input when attempting to value a firm.
Atea Pharmaceuticals is projected to generate 0.8567 in earnings per share on 31st of December 2021. Atea Pharmaceuticals earnings estimates module stress-tests analyst consensus about projected Atea Pharmaceuticals EPS (Earning Per Share) to derive its highest and lowest estimates based on its historical volatility. Please continue to Trending Equities.

Search Earnings Estimates 

 
Refresh
As of 07/26/2021, Gross Profit is likely to drop to about 43.5 M. In addition to that, Profit Margin is likely to drop to -0.22

Atea Pharmaceuticals Earnings Estimation Breakdown

Calculation of earning per share of Atea Pharmaceuticals is based on official Zacks consensus of 2 analysts regarding Atea Pharmaceuticals future annual earnings. Given the historical accuracy of 60.92%, the future earnings per share of Atea Pharmaceuticals is estimated to be 0.8567 with the lowest and highest values of -0.48 and 1.58, respectively. Please note that this consensus of annual earnings estimates for Atea Pharmaceuticals is an estimate of EPS before non-recurring items and including employee stock options expenses
Current EPS
-0.64
26th of July 2021
-0.48
Lowest
Estimated EPS
0.8567
1.58
Highest

Atea Pharmaceuticals Earnings Projection Consensus

Suppose the current estimates of Atea Pharmaceuticals' value are higher than the current market price of the Atea Pharmaceuticals stock. In this case, investors may conclude that Atea Pharmaceuticals is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Atea Pharmaceuticals' stock will quickly adjusts to the new information provided by the consensus estimate.
Number of AnalystsHistorical AccuracyCurrent EPSEPS Estimate for 31st of December 2021

2

60.92%

-0.64

0.8567

Atea Pharmaceuticals Earnings History

Earnings estimate consensus by Atea Pharmaceuticals analysts from Wall Street is used by the market to judge Atea Pharmaceuticals' stock performance. The investors also use these earnings estimates to evaluate and project the stock performance into the future in order to make their investment decisions. However, we recommend analyzing not only Atea Pharmaceuticals' upcoming profit reports and earnings-per-share forecasts but also compare them to our different valuation methods.

Atea Pharmaceuticals Quarterly Earnings Before Interest Taxes and Depreciation Amortization EBITDA

30.72 MillionShare
As of 07/26/2021, Accumulated Retained Earnings Deficit is likely to drop to about (70.3 M). In addition to that, Earning Before Interest and Taxes EBIT is likely to drop to about (11.8 M) As of 07/26/2021, Issuance Purchase of Equity Shares is likely to grow to about 394.1 M, while Weighted Average Shares is likely to drop slightly above 19.4 M.
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Atea Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Atea Pharmaceuticals in the context of predictive analytics.
Hype
Prediction
LowEstimated ValueHigh
19.2625.0830.90
Details
Intrinsic
Valuation
LowReal ValueHigh
20.7426.5632.38
Details
4 Analysts
Consensus
LowTarget PriceHigh
31.0033.0035.00
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Atea Pharmaceuticals. Your research has to be compared to or analyzed against Atea Pharmaceuticals' peers to derive any actionable benefits. When done correctly, Atea Pharmaceuticals' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Atea Pharmaceuticals. Note that many institutional investors and large investment bankers can move markets due to the volume of Atea Pharmaceuticals assets they manage. They also follow analysts to some degree and often drive overall investor sentiments towards Atea Pharmaceuticals. With so many stockholders watching consensus numbers, the difference between actual and projected earnings is one of the most critical factors driving Atea Pharmaceuticals stock price in the short term.

Atea Pharmaceuticals Earnings per Share Projection vs Actual

Actual Earning per Share of Atea Pharmaceuticals refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Atea Pharmaceuticals predict the company's earnings will be in the future. The higher the earnings per share of Atea Pharmaceuticals, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.

Atea Pharmaceuticals Estimated Earnings per Share

For an investor who is primarily interested in generating an income out of investing in entities such as Atea Pharmaceuticals, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Atea Pharmaceuticals should always be considered in relation to other companies to make a more educated investment decision.

Atea Pharmaceuticals Quarterly Analyst Estimates and Surprise Metrics

Earnings surprises can significantly impact Atea Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2021-05-13
2021-03-31-0.05420.340.3942727 
2021-03-30
2020-12-310.2472.622.373960 
2020-12-10
2020-09-30-1.81-1.740.07

About Atea Pharmaceuticals Earnings Estimate

The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Atea Pharmaceuticals earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Atea Pharmaceuticals estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Atea Pharmaceuticals fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.
Last ReportedProjected for 2021
Accumulated Retained Earnings Deficit-65.2 M-70.3 M
Earning Before Interest and Taxes EBIT-10.9 M-11.8 M
Earnings per Basic Share(0.51) (0.55) 
Earnings per Diluted Share(0.51) (0.55) 
Price to Earnings Ratio(73.73) (79.55) 
Earnings Before Interest Taxes and Depreciation Amortization EBITDA-10.9 M-11.8 M
Earnings before Tax-10.9 M-11.8 M
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. The company was incorporated in 2012 and is headquartered in Boston, Massachusetts. Atea Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Atea Pharmaceuticals without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Portfolio Rebalancing Now

   

Portfolio Rebalancing

Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
All  Next Launch Module

Pair Trading with Atea Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Atea Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Atea Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Atea Pharmaceuticals Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for Atea Pharmaceuticals and Equillium. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Please continue to Trending Equities. Note that the Atea Pharmaceuticals information on this page should be used as a complementary analysis to other Atea Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.

Complementary Tools for Atea Pharmaceuticals Stock analysis

When running Atea Pharmaceuticals price analysis, check to measure Atea Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atea Pharmaceuticals is operating at the current time. Most of Atea Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Atea Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Atea Pharmaceuticals' price. Additionally, you may evaluate how the addition of Atea Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Go
The market value of Atea Pharmaceuticals is measured differently than its book value, which is the value of Atea Pharmaceuticals that is recorded on the company's balance sheet. Investors also form their own opinion of Atea Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Atea Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Atea Pharmaceuticals' market value can be influenced by many factors that don't directly affect Atea Pharmaceuticals underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Atea Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Atea Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Atea Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.